UNSPSC 51432303: Moxonidine

This classification denotes an antihypertensive agent with the molecular formula C9H12ClN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CC6X0L40GW, chemically known as 5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl- (9ci) but generally known as moxonidine, which bears US NIH Compound Identifier 4810. European Medicines Agency schedules Moxonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09092MIG. The term MOXONIDINE is an International Non-Proprietary Name.

UNSPSC 51432303 Moxonidine, a Commodity code, represents pharmaceutical procurement by state and local governments for advanced life support and emergency medical services, though recent solicitations show state and local buying concentrated on broader categories of emergency medications and generic pharmaceuticals rather than moxonidine specifically. State and local issuing bodies under this code include municipal fire rescue departments, state health agencies, and cooperative purchasing consortia serving multi-state government facilities. The City of Tampa's Purchasing Department solicited advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue through an IFB; the Texas Health and Human Services Commission issued an RFI regarding direct-to-manufacturer prescription programs to inform future pharmacy benefit procurement strategy; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products through an RFP for distribution across participating state and local facilities in Minnesota and Oregon. Scope under the code encompasses emergency medications, generic pharmaceuticals, and over-the-counter products supplied through authorized wholesalers to fire rescue operations, state health agencies, and cooperative purchasing members, with vendors required to meet FDA compliance, cGMP and DSCSA certification, minimum shelf-life requirements, Safety Data Sheets documentation, and accessibility standards where applicable.

Recent activity appears concentrated in the South, upper Midwest, and multistate cooperative networks. The City of Tampa (Florida) issued IFB 26P00188 with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00, including a 5 percent bid discount for Small Local Business Enterprise participation. MMCAP's RFP (S1070000015802) closed March 26, 2026, and covers Minnesota and Oregon with contract effectiveness July 1, 2026, requiring vendors to demonstrate pricing flexibility, maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and comply with a 3 percent administrative fee. The Texas HHS RFI (HHS0017013) posted April 3, 2026, represents early-stage market research rather than a formal procurement opportunity, designed to inform future direct-to-manufacturer contracting models. No recent opportunities reference moxonidine by name in the source material; the code's actual buying activity appears directed toward broader emergency medication and generic pharmaceutical categories supplied through established wholesale channels and cooperative purchasing vehicles.